Comparison of the effects of atherosclerosis and nitrate therapy on responses to nitric oxide and endothelin-1 in human arteries in vitro.
The effect of previous nitrate therapy on vascular responses to endothelin-1 (ET-1) and NO was investigated in human internal mammary artery (IMA) in vitro. Cumulative concentration-response curves to ET-1 were constructed in rings of IMA and the data grouped into IMA from patients given nitrates prior to the bypass graft operation (nitrate group) and IMA from patients who were not prescribed nitrates (control group). No significant differences were observed between the two groups, either in EC(50) value [P>0.05; 3.5 nM (2.4-5.3 nM; 95% confidence interval) and 4.8 (2.2-10 nM), nitrate and control groups respectively] or E(max) (P>0.05; 78+/-7.5% and 85+/-9.5%, nitrate and control group respectively). No significant differences in concentration-response curves to the NO-donor diethylamine NONOate (DEA/NO) in rings of IMA pre-constricted with 10 nM ET-1 were observed between control and nitrate groups [P>0.05; EC(50) values 0.59 (0.21-1.7) microM and 0.17 (0.03-0.87) microM; E(max) 110+/-5.7% and 112+/-4.5%, nitrate and control groups respectively]. Concentration-response curves to DEA/NO constructed in normal coronary artery were not significantly different from those in coronary artery obtained from patients with ischaemic heart disease (IHD) [P>0.05; E(max) 124+/-11% and 138+/-20%; EC(50) 0.08 (0.02-0.30) microM and 0.23 (0.02-24) microM, normal and IHD respectively]. These data indicate that nitrate therapy does not induce long-term changes in the ET signalling pathway. Furthermore, the tolerance to nitrate therapy is likely to be because of impaired bio-transformation of the drug rather than reduced sensitivity of the media to NO. The similar responses to DEA/NO in normal and atherosclerotic coronary artery suggests that the reduced vasodilator responses in IHD is because of a dysfunctional endothelium and is not mediated by changes in the NO signalling pathway of the smooth muscle.
Wiley
Katherine E
KE
Clinical Pharmacology Unit, University of Cambridge, Level 6, ACCI, Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, U.K. kew29@hermes.cam.ac.uk
Davenport
Anthony P
AP
D001161:Arteriosclerosis / Q000188:drug therapy* / Q000378:metabolism; D003331:Coronary Vessels; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1 / Q000494:pharmacology; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology*; D066298:In Vitro Techniques; D008323:Mammary Arteries; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000503:physiopathology*; D009566:Nitrates / Q000627:therapeutic use*; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D009589:Nitrogen Oxides; D018709:Statistics, Nonparametric; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D019332:Endothelin-1; D006834:Hydrazines; D009566:Nitrates; D020030:Nitric Oxide Donors; D009589:Nitrogen Oxides; D014662:Vasoconstrictor Agents; C084012:1,1-diethyl-2-hydroxy-2-nitrosohydrazine